Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactowell is a multi-strain probiotic supplement investigated for its therapeutic potential in patients with alcoholic hepatitis. Developed and studied by researchers at Chuncheon Sacred Heart Hospital, the treatment focuses on modulating the gut-liver axis to reduce the systemic absorption of gut-derived endotoxins such as lipopolysaccharides (LPS). By restoring healthy gut microbiota and improving intestinal barrier function, Lactowell aims to decrease the production of pro-inflammatory cytokines and lower liver enzyme levels (AST and ALT), thereby mitigating alcohol-induced liver injury. It has been evaluated in Phase 4 clinical trials as a 7-day oral therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactowell (Hallym University Chuncheon Sacred Heart Hospital).